2. Mediator Kinase of β-Catenin-Mediated Transcriptional Output
The Mediator complex acts as a crucial component in transcription regulation, in light of its ability to transduce signals from pathway-specific transcription factors (TFs) to regulate RNA polymerase II (RNAPII) activity
[15][16][117,118]. Depending on its functional configuration, the Mediator complex consists of 25 to 30 proteins, which can be classified into four submodules—head, middle, tail and Mediator kinase (Cyclin-dependent kinase 8 (CDK8), 19) module. The CDK8 module contains CDK8 (or its CDK19 paralog), Cyclin C (encoded by CCNC), MED12 and MED13 subunits. CDK19, a highly conserved paralog of CDK8 in vertebrates, shares conservation in the kinase and cyclin binding domain but is divergent at the C-terminal tail
[17][119]. CDK8 and CDK19 are incorporated into the Mediator kinase module by way of binding MED12 in a mutually exclusive manner. Cyclin-dependent kinase (CDK) proteins mainly consist of two types of members, cell cycle progression CDKs, such as CDK1, CDK2 and CDK4/6, and transcriptional CDKs, such as CDK7, CDK9 and CDK8/19
[18][120]. These transcriptional CDKs complex with their cyclin subunit to phosphorylate the C-terminal domain (CTD) of RNAPII, regulating transcription initiation, elongation and mRNA processing
[19][121]. Unlike CDK7 and CDK9, CDK8/19 activity is dispensable for general transcription regulation and normal cell growth. Recently, the CDK8 kinase function has been linked to an “activation helix” placed by MED12 close to the CDK8 T-loop
[20][122]. CDK8/19 acts downstream of several transcription factors, such as HIF-1α
[21][123] and NFκB
[22][124], to transcribe their target genes. In addition, apart from its action on RNAPII, CDK8 phosphorylates some TFs, such as SMAD, to regulate β/BMP signalling
[23][125]. CDK8/19 is associated with diverse TFs to selectively enhance the expression of silent genes, implying their regulation is in a context-specific manner.
CDK8/19 has been implicated in several cancers, especially those induced by dysregulated gene expression rather than mutations
[24][126]. It has been more than a decade since CDK8 was identified as an oncoprotein in colon cancer. CDK8 was found to act, in a kinase-dependent manner, as a driver of β-catenin-dependent transcription and colorectal cancer proliferation
[25][127]. The underlying molecular mechanisms of how CDK8 regulates β-catenin-dependent transcription are less-well defined, especially considering that the critical kinase substrates of CDK8 that mediate this activity are yet to be identified. Converging genetic studies have demonstrated that the ability of CDK8 to drive β-catenin-regulated gene expression is likely Mediator complex dependent. Aside from CDK8, Mediator kinase submodule proteins MED12 and MED13 have been implicated in recruiting Mediator to Wnt-directed target genes and regulating β-catenin transcriptional output
[26][27][128,129]. Furthermore, repressing the CDK8 co-factor, Cyclin C, produces similar influences on β-catenin-mediated transcription as the inhibition of CDK8
[25][127]. Nevertheless, it has also been proposed that CDK8 can exert its effects on β-catenin indirectly via potentially Mediator-independent mechanisms. Morris et al. suggested pRB and CDK8 can counteract the inhibition of E2F1 on β-catenin-regulated transcription to enhance the expression of Wnt/β-catenin genes
[28][130]. Indeed, chromosomal copy number gains in both
CDK8 and
RB1 loci on 13q in colorectal cancer cells provide a clear explanation of how they select optimal conditions to antagonise E2F1 suppressions
[25][28][127,130]. E2F1 can post-translationally degrade β-catenin
[28][130] and can activate ICAT which disrupts β-catenin-TCF/LEF complex
[29][131]. The physical interaction between CDK8 and E2F1 at the promoters of β-catenin targets, such as
MYC, provides a basis for understanding how Mediator kinase may enhance β-catenin transcriptional output
[28][130]. Subsequent studies have further demonstrated that CDK8 phosphorylates Ser375 on E2F1 in colon cancer cells. This phosphorylation alleviates the E2F1 repressive effects on β-catenin-associated transcription
[30][132]. Together, these data imply that E2F1 could be one of the crucial substrates of CDK8 to enable its regulation on Wnt/β-catenin transcriptional output. Moreover, a recent study identifies YAP as a novel substrate of CDK8. In Hippo signalling, YAP is phosphorylated directly by CDK8 to induce its function, and the phosphorylated YAP can be regulated further by Zyxin, a zinc-binding phosphoprotein, to promote cell proliferation and migration in CRC
[31][133]. In conclusion, CDK8 kinase activity plays an essential role in driving oncogenic events. It can activate different substrates that are associated with intestinal neoplasia and tumour progression. Accordingly, it is quite possible that therapeutic interventions targeting its kinase activity could have clinical value in the treatment of CRC.
3. Chromatin States Regulate β-Catenin-Mediated Transcriptional Output
Chromatin remodeling is an essential step for transcription regulation. The nucleosome, the basic subunit of chromatin, is composed of histones H2A, H2B, H3, H4 and 146 base pairs (bp) of DNA. These histone tails undergo diverse post-translational modifications, such as acetylation, methylation, phosphorylation, ubiquitination, sumoylation and ADP ribosylation. Such modifications can increase or decrease the accessibility of DNA for transcriptional regulators to coordinate gene expression
[32][33][34][134,135,136]. Histone acetyltransferases (HATs) and deacetylases (HDACs) are associated with enhanced and decreased acetylation, which mark gene activation and repression, respectively
[35][137]. Furthermore, histone methylation can both alter chromatin accessibility and epigenetically activate or inactivate gene expression. The dynamic balance between histone methylation and demethylation is mediated by histone methyltransferases (HMTs) and demethylases (HDMs), respectively
[36][138]. In addition to histone modification, chromatin remodeling is also an important epigenetic event. ATP-dependent remodeling complexes can alter the location and configuration of the nucleosome, and the changed chromatin can participate in either gene activation or inhibition
[35][137]. Epigenetic regulation is involved in various events, including transcription, replication, repair and genome stability. Lastly, chromatin modifiers have been reported to have essential influences on cancer etiology
[37][38][39][139,140,141]. In Wnt signalling, various chromatin modifiers have been identified as activators or repressors of Wnt/β-catenin transcriptional outputs (
Figure 35).
Figure 35. Overview of chromatin modifiers involved in β-catenin-dependent transcriptional regulation and their roles in the Wnt pathway. HATs (histone acetyltransferases, transferring acetyl groups to histones): CBP (CREB-binding protein)/p300, PCAF (p300/CBP-associated factor), TRRAP (Transformation/transcription domain-associated protein)/TIP60; HDACs (Histone deacetylase, removing acetyl groups from histones): HDAC1 (Histone deacetylase 1), HDAC2 (Histone deacetylase 2), SIRT1 (NAD-dependent deacetylase sirtuin-1); HMTs (Histone methyltransferases, transferring methyl groups to histones): MLL1 (Mixed-lineage leukemia 1 or Histone-lysine N-methyltransferase 2A), hSETD1A (human SET domain containing protein 1A), EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit), SET8 (SET domain-containing protein 8), SETDB1 (SET domain bifurcated 1), DOT1L (DOT1 like histone lysine methyltransferase), PRMT5 (Protein arginine N-methyltransferase 5); HDMs (Histone demethylases, removing methyl groups from histones): KDM3 (Lysine-specific demethylase 3), KDM3A (Lysine demethylase 3A), KDM4D (Lysine-specific demethylase 4D), KDM1A (Lysine demethylase 1A); SWI/SNF: BRG1 (Transcription activator BRG1), SNF5 (BRG1-associated factor 47), BAF57 (BRG1-associated factor 57), AGGF1 (Angiogenic factor with G patch and FHA domains 1), ARID1A (AT-rich interactive domain-containing protein 1A), ARID1B (AT-rich interactive domain-containing protein 1B).
6. Therapeutic Strategy
The clinical implications of targeting the Wnt signalling pathway has been recognised for decades. Nevertheless, this has not been translated into the clinic for reasons detailed below. Dysregulated Wnt pathway can be targeted at three different levels: the Wnt-receptor complex, the cytoplasmic destruction complex and the nuclear β-catenin-TCF/LEF complex. Regulators involved in downstream transcriptional levels emerge as the most attractive targets for drug development. The implications of APC loss in the vast majority of CRC make inhibitors targeting Wnt signalling components upstream of the destruction complex ineffective. One exception is CRCs harbouring RSPO2/3 fusions
[40][209]. While accounting for only 1–3% of CRC cases, the ability to therapeutically target RSPO2/3 fusion driven CRCs offers a proof of concept evidence that specific cancer targeting for the Wnt pathway can be achieved
[41][210]. Recent studies in human colon organoids and in in silico genetic interaction analysis provide a model of how homeostatic and oncogenic Wnt responses can be untangled and stratified
[42][43][211,212]. Diverse transcriptional regulators provide potential avenues to identify those only contributing to tumourigenesis. This diversity within this growing toolbox of targets offers opportunities to design rational therapies that will specifically target oncogenic signalling with minimal normal toxicities.
Disrupting protein–protein interactions in transcriptional complexes opens a new therapeutic window for anti-cancer drug development, although the transient nature of some interactions hinders effective drug development. Currently, most of the inhibitors targeting transcriptional level in Wnt pathway attempt to disrupt β-catenin-TCF4 interactions
[44][45][46][47][48][49][213,214,215,216,217,218]. In addition, inhibitors interfering with the interaction between β-catenin and CBP may be suggested as attractive candidates
[50][51][52][53][219,220,221,222]. Recently, in APC-deficient models, it was demonstrated that abrogation of BCL9/9L cannot affect intestinal homeostasis, but can negatively influence intestinal neoplasia, thus highlighting the therapeutic potential of targeting the interaction between β-catenin and BCL9/9L
[54][55][223,224]. Kinase inhibitors are a mainstay of cancer therapies. The ability of a specific CDK8/19 kinase inhibitor, CCT251545, inhibits Wnt pathway-induced tumours in mouse models
[56][225]. Similarly, another kinase, YES1, implicated in YAP dependent β-catenin transcriptional output, can be inhibited by CH6953755 to restrict YES1-YAP1-dependent tumour growth
[57][58][94,226]. Lastly, NSC48300, a pharmacologic inhibitor for Taspase1, can effectively inactivate breast and brain tumour growth via preventing the formation of a mature MLL1 complex
[59][227]. Current inhibitors and their drug development status are summarised in
Table 12.
Table 12.
Summary of potential therapeutic strategies and inhibitors targeting dysregulated Wnt pathway.
Epigenetic modifications are reversible, thus attracting extensive attention to targeting abnormal epigenetic events so as to revert the cancer phenotype to a normal state. Despite promising therapeutic potential in hematopoietic malignancies, it is not clear why epigenetic inhibitors exert less efficacy in solid tumours. Currently, drugs targeting epigenetic regulators directly in CRC are missing. Resistant mechanisms need to be explored to provide a better opportunity for the development of epigenetic drugs in solid cancers.